MiMedx Group (MDXG) Earnings Date & Reports

Key Takeaways

• MiMedx reported third quarter 2026 net sales of $62.3 million, down from $113.7 million in the prior-year period.
• The company posted a GAAP net loss of $8.7 million, or $0.06 per share, versus net income of $16.7 million, or $0.11 per share, a year earlier.
• Surgical sales grew 9% year over year to $40.0 million, while Wound sales declined to $22.3 million from $77.1 million.
• Adjusted earnings per share (EPS) of negative $0.01 and revenue of $62.28 million both came in below consensus estimates of $0.00 and $68.72 million.
• The company returned to positive Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) and ended the quarter debt-free with $120.8 million in cash.
• Full-year 2026 net sales guidance was lowered to a range of $250 million to $260 million.
• For additional context, explore MiMedx's Major News, Today's Price Move, Price Targets, and Forecast pages.
• Discover actionable trading ideas with Trending AI Robots.

Earnings Context and Why It Matters

MiMedx Group is navigating a pivotal transition as its business pivots from wound care toward its faster-growing Surgical franchise. The third quarter was heavily shaped by Medicare reimbursement changes that took effect on January 1, 2026 and have pressured the company's Wound segment. Surgical now represents nearly two-thirds of net sales, a structural shift management has framed as central to its long-term strategy. This quarter also followed a roughly $40 million cost-reduction program announced earlier in 2026, making the return to positive Adjusted EBITDA a key proof point for investors. The results matter because they test whether MiMedx can stabilize profitability and offset wound care headwinds through surgical momentum.

Reported Results

MiMedx reported third quarter 2026 net sales of $62.3 million, a sharp decline from $113.7 million in the same period last year. Surgical sales rose 9% to $40.0 million, while Wound sales fell to $22.3 million from $77.1 million. The company posted a GAAP (Generally Accepted Accounting Principles) net loss of $8.7 million, or $0.06 per basic and diluted share, compared with net income of $16.7 million, or $0.11 per share, a year ago.

On an adjusted basis, EPS came in at negative $0.01, below the consensus estimate of $0.00, while revenue of $62.28 million fell short of the $68.72 million consensus. Gross profit was $49.7 million, reflecting an 80% gross margin, and selling, general, and administrative (SG&A) expenses declined to $58.3 million from $69.0 million. MiMedx returned to positive Adjusted EBITDA during the quarter. The company ended the period with $120.8 million in cash and cash equivalents and no debt outstanding after repaying its remaining term loan balance. Management also lowered full-year 2026 net sales guidance to $250 million to $260 million and announced a patent license agreement expected to provide $25 million in five $5 million installments.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors monitoring the healthcare and medical technology space, it offers a streamlined way to surface potential setups and track evolving market conditions.

Market Reaction and Investor Sentiment

The third quarter results landed below consensus expectations on both the top and bottom lines, with adjusted EPS of negative $0.01 and revenue of $62.28 million trailing analyst estimates. Investor attention is likely to center on the contrasting trajectories of the company's two segments: sustained mid-teens volume growth in Surgical against a Wound business still absorbing the impact of Medicare reimbursement changes. The return to positive Adjusted EBITDA and a debt-free balance sheet provide a measure of financial stability, while the reduced full-year guidance signals that management expects near-term pressure to persist. Sentiment around the stock will likely be shaped by how quickly surgical momentum can offset the wound care decline.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will want to track whether MiMedx can sustain the momentum in its Surgical franchise, which management has positioned as the primary growth engine. Surgical volumes grew at a mid-teens rate against a strong prior-year comparison, even amid softer U.S. surgical procedure volumes, and now represent nearly two-thirds of net sales.

The Wound segment remains the key variable. The Medicare reimbursement framework introduced in early 2026 has reshaped pricing and demand dynamics, and any stabilization or recovery in wound care volumes will be closely watched. Management's sequential progress in wound volume during recent quarters suggests the market is adapting, but the path remains uneven.

Cost discipline is another important factor. The company's earlier restructuring actions have helped return the business to positive Adjusted EBITDA, and investors will monitor whether those savings hold while the company continues to invest in new product launches and pipeline development.

Finally, the lowered full-year net sales guidance of $250 million to $260 million will serve as a benchmark for execution through the fourth quarter. Balance sheet strength, including $120.8 million in cash and no debt, gives the company flexibility as it navigates the transition.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations